Assessment of Corticosteroid Therapy and Death or Disability According to Pretreatment Risk of Death or Bronchopulmonary Dysplasia in Extremely Preterm Infants
- PMID: 37155165
- PMCID: PMC10167571
- DOI: 10.1001/jamanetworkopen.2023.12277
Assessment of Corticosteroid Therapy and Death or Disability According to Pretreatment Risk of Death or Bronchopulmonary Dysplasia in Extremely Preterm Infants
Abstract
Importance: Meta-analyses suggest that corticosteroids may be associated with increased survival without cerebral palsy in infants at high risk of bronchopulmonary dysplasia (BPD) but are associated with adverse neurologic outcomes in low-risk infants. Whether this association exists in contemporary practice is uncertain because most randomized clinical trials administered corticosteroids earlier and at higher doses than currently recommended.
Objective: To evaluate whether the pretreatment risk of death or grade 2 or 3 BPD at 36 weeks' postmenstrual age modified the association between postnatal corticosteroid therapy and death or disability at 2 years' corrected age in extremely preterm infants.
Design, setting, and participants: This cohort study analyzed data on 482 matched pairs of infants from 45 participating US hospitals in the National Institute of Child Health and Human Development Neonatal Research Network Generic Database (GDB). Infants were included in the cohort if they were born at less than 27 weeks' gestation between April 1, 2011, and March 31, 2017; survived the first 7 postnatal days; and had 2-year death or developmental follow-up data collected between January 2013 and December 2019. Corticosteroid-treated infants were propensity score matched with untreated controls. Data were analyzed from September 1, 2019, to November 30, 2022.
Exposure: Systemic corticosteroid therapy to prevent BPD that was initiated between day 8 and day 42 after birth.
Main outcomes and measures: The primary outcome was death or moderate to severe neurodevelopmental impairment at 2 years' corrected age. The secondary outcome was death or moderate to severe cerebral palsy at 2 years' corrected age.
Results: A total of 482 matched pairs of infants (mean [SD] gestational age, 24.1 [1.1] weeks]; 270 males [56.0%]) were included from 656 corticosteroid-treated infants and 2796 potential controls. Most treated infants (363 [75.3%]) received dexamethasone. The risk of death or disability associated with corticosteroid therapy was inversely associated with the estimated pretreatment probability of death or grade 2 or 3 BPD. The risk difference for death or neurodevelopmental impairment associated with corticosteroids decreased by 2.7% (95% CI, 1.9%-3.5%) for each 10% increase in the pretreatment risk of death or grade 2 or 3 BPD. This risk transitioned from estimated net harm to benefit when the pretreatment risk of death or grade 2 or 3 BPD exceeded 53% (95% CI, 44%-61%). For death or cerebral palsy, the risk difference decreased by 3.6% (95% CI, 2.9%-4.4%) for each 10% increase in the risk of death or grade 2 or 3 BPD and transitioned from estimated net harm to benefit at a pretreatment risk of 40% (95% CI, 33%-46%).
Conclusions and relevance: Results of this study suggested that corticosteroids were associated with a reduced risk of death or disability in infants at moderate to high pretreatment risk of death or grade 2 or 3 BPD but with possible harm in infants at lower risk.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10167571/bin/jamanetwopen-e2312277-g001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10167571/bin/jamanetwopen-e2312277-g002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10167571/bin/jamanetwopen-e2312277-g003.gif)
Similar articles
-
Corticosteroids for the prevention and treatment of bronchopulmonary dysplasia: an overview of systematic reviews.Cochrane Database Syst Rev. 2024 Apr 10;4(4):CD013271. doi: 10.1002/14651858.CD013271.pub2. Cochrane Database Syst Rev. 2024. PMID: 38597338 Review.
-
Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD010941. doi: 10.1002/14651858.CD010941.pub3. Cochrane Database Syst Rev. 2023. PMID: 36912887 Free PMC article. Review.
-
Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.Cochrane Database Syst Rev. 2017 Jan 31;1(1):CD010941. doi: 10.1002/14651858.CD010941.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2023 Mar 13;3:CD010941. doi: 10.1002/14651858.CD010941.pub3. PMID: 28141913 Free PMC article. Updated. Review.
-
Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.Cochrane Database Syst Rev. 2017 Oct 24;10(10):CD001146. doi: 10.1002/14651858.CD001146.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2021 Oct 21;10:CD001146. doi: 10.1002/14651858.CD001146.pub6. PMID: 29063585 Free PMC article. Updated. Review.
-
Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.Cochrane Database Syst Rev. 2021 Nov 11;11(11):CD001145. doi: 10.1002/14651858.CD001145.pub5. Cochrane Database Syst Rev. 2021. PMID: 34758507 Free PMC article. Review.
Cited by
-
Corticosteroids for the prevention and treatment of bronchopulmonary dysplasia: an overview of systematic reviews.Cochrane Database Syst Rev. 2024 Apr 10;4(4):CD013271. doi: 10.1002/14651858.CD013271.pub2. Cochrane Database Syst Rev. 2024. PMID: 38597338 Review.
-
Effects of postnatal corticosteroids on lung development in newborn animals. A systematic review.Pediatr Res. 2024 Mar 16. doi: 10.1038/s41390-024-03114-6. Online ahead of print. Pediatr Res. 2024. PMID: 38493255
-
Prediction of bronchopulmonary dysplasia in very preterm infants: competitive risk model nomogram.Front Pediatr. 2024 Feb 20;12:1335891. doi: 10.3389/fped.2024.1335891. eCollection 2024. Front Pediatr. 2024. PMID: 38445078 Free PMC article.
-
Maternal cobalt concentration and risk of spontaneous preterm birth: the role of fasting blood glucose and lipid profiles.Front Nutr. 2024 Feb 1;11:1336361. doi: 10.3389/fnut.2024.1336361. eCollection 2024. Front Nutr. 2024. PMID: 38362103 Free PMC article.
-
Stem/Progenitor Cells and Related Therapy in Bronchopulmonary Dysplasia.Int J Mol Sci. 2023 Jul 7;24(13):11229. doi: 10.3390/ijms241311229. Int J Mol Sci. 2023. PMID: 37446407 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
- U10 HD021373/HD/NICHD NIH HHS/United States
- UG1 HD087226/HD/NICHD NIH HHS/United States
- UM1 TR004409/TR/NCATS NIH HHS/United States
- UL1 TR000442/TR/NCATS NIH HHS/United States
- UG1 HD027856/HD/NICHD NIH HHS/United States
- UG1 HD034216/HD/NICHD NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- UG1 HD027904/HD/NICHD NIH HHS/United States
- UG1 HD053109/HD/NICHD NIH HHS/United States
- UG1 HD027851/HD/NICHD NIH HHS/United States
- UG1 HD068278/HD/NICHD NIH HHS/United States
- UG1 HD068263/HD/NICHD NIH HHS/United States
- K23 HL136843/HL/NHLBI NIH HHS/United States
- UL1 TR002538/TR/NCATS NIH HHS/United States
- UG1 HD068270/HD/NICHD NIH HHS/United States
- UG1 HD068244/HD/NICHD NIH HHS/United States
- UG1 HD027853/HD/NICHD NIH HHS/United States
- UG1 HD112093/HD/NICHD NIH HHS/United States
- UL1 TR000042/TR/NCATS NIH HHS/United States
- UG1 HD087229/HD/NICHD NIH HHS/United States
- UL1 TR000006/TR/NCATS NIH HHS/United States
- UG1 HD040689/HD/NICHD NIH HHS/United States
- UG1 HD053089/HD/NICHD NIH HHS/United States
- UL1 TR000093/TR/NCATS NIH HHS/United States
- UL1 TR000041/TR/NCATS NIH HHS/United States
- UG1 HD068284/HD/NICHD NIH HHS/United States
- UG1 HD021385/HD/NICHD NIH HHS/United States
- UG1 HD040492/HD/NICHD NIH HHS/United States
- UG1 HD021364/HD/NICHD NIH HHS/United States
- UG1 HD027880/HD/NICHD NIH HHS/United States
- UL1 TR000105/TR/NCATS NIH HHS/United States
- UL1 TR001117/TR/NCATS NIH HHS/United States
- UL1 TR000077/TR/NCATS NIH HHS/United States